{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:06:43Z","timestamp":1793740003450,"version":"4.6.1"},"reference-count":16,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Aim: To investigate the possible relationship between fecal calprotectin (FC) level and ultrasound indicators of steatosis and fibrosis wich defined by attenuation coefficient (AC) and liver stiffness (LS) from two-dimensional (2D) shear-wave elastography (SWE) in patients with metabolically associated fatty liver disease (MAFLD). \nMaterials and Methods: The study included 110 persons with MAFLD; mean age 51.3\u00b14.8 years, 65 (59.1%) men. There were used laboratory, sonography and statistical methods. \nResults: Stage S1 of steatosis was diagnosed in 42 (38.2%), S2 - in 56 (50.9%), S3 - only in 12 (10.9%) MAFLD patients. The carbohydrate metabolism disorders were found in 62 (56.4%); 38 (34.5%) patients among them suffered from type 2 diabetes. The lipid metabolism disorders were diagnosed in the vast majority of patients included in this study. The minimal excess of fecal calprotectin (FC) was detected in 72 MAFLD patients (65.5%), the moderate increase of FC was found in 12 persons, the FC more than 10-fold excess of the norm was observed in only 8 MAFLD patients. FC levels were significantly elevated in MAFLD patients with a S2-S3 compared to those with a S1 (75.8 [42.9\u2013112.1] vs. 46.3 [28.2\u201365.4], p&lt;0.01). \nConclusions: Fecal calprotectin levels are significantly elevated in patients with MAFLD. Future studies are warranted to establish the definitive role and clinical utility of FC as a potential biomarker of probably liver steatosis as well as other diseases associated with methabolic syndrome and its complications.<\/jats:p>","DOI":"10.36740\/merkur202304105","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:25:15Z","timestamp":1695749115000},"page":"330-333","source":"Crossref","is-referenced-by-count":2,"title":["IS FECAL CALPROTECTIN DETERMINATION USEFUL FOR PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE?"],"prefix":"10.36740","volume":"51","author":[{"given":"Snizhana V.","family":"Feysa","sequence":"first","affiliation":[{"name":"STATE HIGHER EDUCATIONAL ESTABLISHMENT \u201cUZHHOROD NATIONAL UNIVERSITY\u201d, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Pushkarenko","sequence":"additional","affiliation":[{"name":"STATE HIGHER EDUCATIONAL ESTABLISHMENT \u201cUZHHOROD NATIONAL UNIVERSITY\u201d, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana O.","family":"Rudakova","sequence":"additional","affiliation":[{"name":"STATE HIGHER EDUCATIONAL ESTABLISHMENT \u201cUZHHOROD NATIONAL UNIVERSITY\u201d, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina V.","family":"Varvarynets","sequence":"additional","affiliation":[{"name":"STATE HIGHER EDUCATIONAL ESTABLISHMENT \u201cUZHHOROD NATIONAL UNIVERSITY\u201d, UZHHOROD, UKRAINE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Bourgonje AR, van den Berg EH, Kieneker LM et al. Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population. Int J Mol Sci. 2022;23(24):15708. doi:10.3390\/ijms232415708.","DOI":"10.3390\/ijms232415708"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol. 2013;218(3):25\u201336. doi: 10.1530\/JOE-13-0201.","DOI":"10.1530\/joe-13-0201"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Liu K, Wang FS, Xu R. Neutrophils in liver diseases: Pathogenesis and therapeutic targets. Cell Mol. Immunol. 2021;18(1):38\u201344. doi: 10.1038\/s41423-020-00560-0.","DOI":"10.1038\/s41423-020-00560-0"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: From occult blood to molecular markers of intestinal inflammation and damage. Gut. 2009;58:859\u2013868. doi: 10.1136\/gut.2008.170019.","DOI":"10.1136\/gut.2008.170019"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Wang S, Song R, Wang Z et al. S100A8\/A9 in Inflammation. Front Immunol. 2018; 9:1298. doi: 10.3389\/fimmu.2018.01298.","DOI":"10.3389\/fimmu.2018.01298"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Teng TS, Ji AL, Ji XY et al. Neutrophils and Immunity: From Bactericidal Action to Being Conquered. J Immunol Res. 2017:9671604. doi: 10.1155\/2017\/9671604.","DOI":"10.1155\/2017\/9671604"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Bourgonje AR, von Martels JZH, de Vos P et al. Increased fecal calprotectin levels in Crohn\u2019s disease correlate with elevated serum Th1- and Th17-associated cytokines. PLoS ONE. 2018;13:e0193202. doi:10.1371\/journal.pone.0193202.","DOI":"10.1371\/journal.pone.0193202"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. B\u0131\u00e7ak\u00e7\u0131 E, Demirta\u015f CO, \u00c7elikel \u00c7 et al. Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of inflammation and fibrosis in non-alcoholic steatohepatitis. Turk J Gastroenterol. 2020;31:681\u2013687. doi: 10.5152\/tjg.2020.19403.","DOI":"10.5152\/tjg.2020.19403"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Cai Q, Zhu J, Cui X et al. S100A9 promotes inflammatory response in diabetic nonalcoholic fatty liver disease. Biochem Biophys Res Commun. 2022;618:127\u2013132. doi: 10.1016\/j.bbrc.2022.06.026.","DOI":"10.1016\/j.bbrc.2022.06.026"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Liu X, Wang Y, Ming Y et al. S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis. PLoS ONE. 2015:10:e0127352. doi:10.1371\/journal.pone.0127352.","DOI":"10.1371\/journal.pone.0127352"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Gao B, Ahmad MF, Nagy LE et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol 2019;70(2):249\u2013259. doi: 10.1016\/j.jhep.2018.10.023.","DOI":"10.1016\/j.jhep.2018.10.023"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Mantovani A, Cassatella MA, Costantini C et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519\u2013531. doi: 10.1038\/nri3024.","DOI":"10.1038\/nri3024"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Serhal R, Hilal G, Boutros G et al. Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. Biomed Res Int. 2015;2015:850246. doi: 10.1155\/2015\/850246.","DOI":"10.1155\/2015\/850246"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Rodrigues RM, He Y, Hwang S et al. E-Selectin-Dependent Inflammation and Lipolysis in Adipose Tissue Exacerbate Steatosis-to-NASH Progression via S100A8\/9. Cell Mol Gastroenterol Hepatol. 2022;13(1):151\u2013171. doi: 10.1016\/j.jcmgh.2021.08.002.","DOI":"10.1016\/j.jcmgh.2021.08.002"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Nacken W, Roth J, Sorg C et al. S100A9\/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003;60(6):569\u2013580. doi: 10.1002\/jemt.10299.","DOI":"10.1002\/jemt.10299"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045\u20132051. doi: 10.1161\/ATVBAHA.108.179705.","DOI":"10.1161\/ATVBAHA.108.179705"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T17:08:23Z","timestamp":1698599303000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2023i4.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]},"published-print":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202304105","archive":["Internet Archive"],"relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}